TGA (Autosaved)

download TGA (Autosaved)

of 34

Transcript of TGA (Autosaved)

  • 8/3/2019 TGA (Autosaved)

    1/34

  • 8/3/2019 TGA (Autosaved)

    2/34

    3. What the TGA regulates

    The TGA is responsible for ensuring that therapeutic goods available for supply in Australia aresafe and fit for their intended purpose. These include goods Australians rely on every day, such

    as vitamin pills and bandaids, through to goods used to treat serious conditions, such asprescription medicines, vaccines, blood products and surgical implants.

    The TGA regulates the supply of:

    medicines prescribed by a doctor or dentist medicines available from behind the pharmacy counter medicines available in the general pharmacy medicines available from supermarkets complementary medicines, these include vitamins, herbal and traditional medicines medical devices, from simple devices like bandages to complex technologies like heart

    pacemakers

    products used to test for various diseases or conditions (in vitro diagnostic devices), such as bloodtests; and

    vaccines, blood products, and other biologics.and the manufacturing and advertising of these products.

    Regulating medicines

    The regulation of medicines includes the following features:

    classifying the medicine based on different levels of risk to the person taking them implementing appropriate regulatory controls for the manufacturing processes of medicines Medicines assessed as having a higher level of risk (prescription medicines, some non-

    prescription medicines) are evaluated for quality, safety and efficacy Medicines having a lower risk (medicines purchased over the counter, such as complementary

    medicines) are assessed for quality and safety Medicines determined to be available for lawful supply by the Therapeutic Goods Administration

    can be identified by either an AUST R number or an AUST L number on the outer packaging.Please note, there are a small number of medicines that are exempt and do not require thisinformation on the label

    Once available for supply, medicines are subject to monitoring by the TGA. This monitoringincludes a comprehensive adverse event reporting programme.

    Regulating medical devices

    The regulation of medical devices includes:

    classifying the medical device based on different levels of risk to the user assessing compliance with a set of internationally agreed essential principles for their quality,

    safety and performance implementing appropriate regulatory controls for the manufacturing processes of medical devices

  • 8/3/2019 TGA (Autosaved)

    3/34

    including the medical device in the Australian Register of Therapeutic Goods Once available for supply, medical devices are subject to monitoring by the TGA. This

    monitoring includes a comprehensive adverse event reporting programme.

    Other therapeutic goods regulated by the TGA

    The TGA also applies a risk management approach to the regulation of:

    In vitro diagnostic medical devices (IVDs) blood blood components plasma derivatives tissue and cellular products tissue and cell based derivatives sterilants and disinfectants

    4. TGA structure16 May 2011

    The Therapeutic Goods Administration (TGA) is a division of the Australian GovernmentDepartment of Health and Ageing. The TGA's offices are grouped into three core groups -Market Authorisation Group, Monitoring and Compliance Group and Regulatory Support Group.

    A.TGA Executive

    The TGA Executive has overall responsibility for the management of the TGA's regulatory

    functions and activities.

    The TGA Executive comprises:

    TGA National Manager, Dr Rohan Hammett Principal Medical Adviser, Dr Megan Keaney Principal Legal Adviser, Ms Philippa Horner Chief Regulatory Officer, Ms Jenny Hefford Principal Adviser (Operations), Mr Stephen Dellar

    B. Market Authorisation Group

    The Market Authorisation Group (MAG) is responsible for undertaking evaluations ofapplications to approve new therapeutic products for supply in Australia. The MAG makesdecisions whether to approve or reject market authorisation of medicines, medical devices andblood and tissues that are imported, exported, manufactured and supplied in Australia.

    The MAG's Group Coordinator is Ms Judy Develin.

    http://www.tga.gov.au/about/tga-structure-hammett.htmhttp://www.tga.gov.au/about/tga-structure-keaney.htmhttp://www.tga.gov.au/about/tga-structure-keaney.htmhttp://www.tga.gov.au/about/tga-structure-hammett.htm
  • 8/3/2019 TGA (Autosaved)

    4/34

    The Offices and Units in the MAG are:

    Office of Medicines Authorisation (OMA)

    Office Head: Dr Harry Rothenfluh

    The OMA is responsible for approving prescription and non-prescription medicines.Office of Complementary Medicines (OCM)

    Office Head: Mr Ian Stehlik

    The OCM is responsible for approving complementary medicines, including traditional andherbal medicines and vitamin and mineral supplements.

    Office of Devices Authorisation (ODA)

    Office Head: Ms Andrea Kunca

    The ODA is responsible for approving medical devices.Office of Scientific Evaluation (OSE)

    Office Head: Dr Mark McDonald

    The OSE provides scientific advice to support the decisions made by the Market AuthorisationGroup.

    This includes clinical, toxicological, biological sciences and pharmaceutical chemistry evaluationof therapeutic products.

    It also includes the Experimental Products Unit which is responsible for the evaluation andauthorisation of certain clinical trials and special access arrangements for all types of therapeuticproducts.

    Group Support Unit (GSU)

    The GSU is responsible for providing planning, coordination and administrative services to allareas of the Group.

    C. Monitoring and Compliance Group

    The Monitoring and Compliance Group (MCG) is responsible for ongoing monitoring oftherapeutic products approved for supply in Australia to ensure they meet the necessarystandards throughout their lifecycle.

    The way our medicines and devices are manufactured is also regulated by the TGA. Australianand international manufacturers must operate in a manner that results in products meetingspecified standards if they are to be supplied in Australia. The TGA conducts regular inspections

    http://www.tga.gov.au/industry/pm.htmhttp://www.tga.gov.au/industry/otc.htmhttp://www.tga.gov.au/industry/cm.htmhttp://www.tga.gov.au/industry/devices.htmhttp://www.tga.gov.au/industry/clinical-trials.htmhttp://www.tga.gov.au/hp/access.htmhttp://www.tga.gov.au/hp/access.htmhttp://www.tga.gov.au/industry/clinical-trials.htmhttp://www.tga.gov.au/industry/devices.htmhttp://www.tga.gov.au/industry/cm.htmhttp://www.tga.gov.au/industry/otc.htmhttp://www.tga.gov.au/industry/pm.htm
  • 8/3/2019 TGA (Autosaved)

    5/34

    of manufacturers, both in Australia and overseas, to ensure they continue to meet thesestandards.

    The MCG's Group Coordinator is Dr Larry Kelly.

    The Offices and Units in the MCG are:

    Office of Product Review (OPR)

    Office Head: Dr Jane Cook

    The OPR is responsible for overseeing all therapeutic products to ensure they continue tomaintain an appropriate level of quality, safety, efficacy and performance following entry into theAustralian marketplace.

    This includes monitoring reports of adverse events and reviewing medicine ingredients anddevice components.

    The Advertising and Recalls Unit also sits within OPR and is responsible for administeringlegislative requests for the advertising of therapeutic goods in Australia and coordinating productrecalls when necessary.

    Office of Laboratories and Scientific Services (OLSS)

    Office Head: Dr Peter Bird

    The OLSS is responsible for conducting laboratory testing, quality assessment and test proceduredevelopment in scientific disciplines such as, microbiology, immunobiology, molecular biology,biochemistry, chemistry, and biomaterials and engineering.

    Office of Manufacturing Quality (OMQ)

    Office Head: Mr Bill Turner

    The OMQ is responsible for ensuring manufacturers of medicines and medical devices meetappropriate standards of quality.

    Group Support Unit (GSU)

    The GSU is responsible for providing planning, coordination and administrative services to allareas of the MCG.

    D. Regulatory Support Group

    The Regulatory Support Group provides whole-of-agency regulatory support services that enablethe TGA to undertake its regulatory responsibilities. This includes the legal, finance, informationtechnology and information management, communications, parliamentary and human resourcemanagement services.

    http://www.tga.gov.au/safety/problem.htmhttp://www.tga.gov.au/industry/advertising.htmhttp://www.tga.gov.au/safety/recalls.htmhttp://www.tga.gov.au/safety/recalls.htmhttp://www.tga.gov.au/about/tga-structure-olss.htmhttp://www.tga.gov.au/about/tga-structure-omq.htmhttp://www.tga.gov.au/about/tga-structure-omq.htmhttp://www.tga.gov.au/about/tga-structure-olss.htmhttp://www.tga.gov.au/safety/recalls.htmhttp://www.tga.gov.au/safety/recalls.htmhttp://www.tga.gov.au/industry/advertising.htmhttp://www.tga.gov.au/safety/problem.htm
  • 8/3/2019 TGA (Autosaved)

    6/34

    The Offices and Units in the Regulatory Support Group are:

    Office of Legal Services (OLS)

    Office Head: Ms Terry Lee

    The OLS provides a full range of legal services for the TGA.Office of Information Management (OIM)

    Office Head: Mr Peter Bickerton

    The OIM manages the delivery of Information Technology and Information Management, recordsmanagement and the TGA library.

    Office of Parliamentary and Strategic Support (OPSS)

    Office Head: Mr Pio Cesarin

    The OPSS provides a strategic, coordinated and whole of agency approach to the management ofthe TGA's communications, parliamentary services and committee support, stakeholder andinternational engagement, cross-agency projects, reforms to the TGA's regulatory operations, andhuman resources.

    Regulatory Compliance Unit

    The Unit is responsible for on-going surveillance, enforcement and related activities, includinginvestigations into illegal and counterfeit therapeutic goods.

    Chief Financial Officer

    Chief Financial Officer: Mr Vinod Mahajan

    The Chief Financial Officer provides oversight of the TGAs finance and property services.Office of Regulatory Integrity

    The Office of Regulatory Integrity (ORI) provides an independent and objective review andadvisory service to provide assurance to the National Manager of the TGA that the TGA'sfinancial and operational controls are operating in an efficient, effective and appropriate mannerand that its regulatory controls are operating in an efficient, effective and appropriate manner andare consistent with relevant legislative requirements.

    ORI activities encompass review activities, especially in relation to compliance and performanceimprovements, compliance activities, advisory services for new programs and assistance withrisk management and fraud control programs and management of TGA's insurance coverage.

  • 8/3/2019 TGA (Autosaved)

    7/34

    The Head of the ORI is Dr Leonie Hunt.

    5. TGA legal expenditure

    28 October 2010

    External legal expenditure 2009-2010

    Paragraph 11.1(da) of the Legal Services Directions 2005 requires agencies regulated by theFinancial Management and Accountability Act 1997 (FMA agencies) to report to the Office ofLegal Services Coordination (OLSC) on their legal services expenditure.

    Paragraph 11.1(ba) of the Legal Services Directions 2005 requires that, by 30 October each year,agencies make publicly available records of the Legal Services Expenditure for the previousyear.

    http://www.comlaw.gov.au/ComLaw/Legislation/LegislativeInstrument1.nsf/0/A174CEB3C7BDDA91CA257107007F5681?OpenDocumenthttp://www.comlaw.gov.au/ComLaw/Legislation/LegislativeInstrument1.nsf/0/A174CEB3C7BDDA91CA257107007F5681?OpenDocument
  • 8/3/2019 TGA (Autosaved)

    8/34

    The Therapeutic Goods Administration total external legal expenditure (GST inclusive) for2009-2010 was as follows:

    External expenditure

    on solicitors

    External expenditure

    on barristers

    External expenditure on other

    disbursements

    Total external

    expenditure

    $878,055 $143,051 $141,186 $1,162,293

    Note: Registration costs associated with the Federal Register of Legislative Instruments and costsfor preparing legislative instrument compilations have not been included.

    Internal legal expenditure 2009-2010

    The Therapeutic Goods Administration total internal legal expenditure (GST inclusive) 2009-2010 was: $3,016,198.57. This represents the cost of maintaining an in-house legal branch (this

    includes administrative staff), which provides all in-house legal services, including advisings,legislation, legal training, briefing on litigation, commercial law, etc.

    6. Freedom of information

    Related information

    Information Publication Scheme Documents released under Section 11C of the FOI Act 1982

    The Freedom of Information Act 1982 (FOI Act) gives you the right to:

    access copies of documents (except exempt documents) we hold ask for information we hold about you to be changed or annotated if it is incomplete, out of date,

    incorrect or misleading, and seek a review of our decision not to allow you access to a document or not to amend your

    personal record.

    You can ask to see any document that we hold. We can refuse access to some documents, orparts of documents that are exempt. Exempt documents may include those relating to nationalsecurity, documents containing material obtained in confidence, material that is commercial-in-

    confidence, Cabinet documents, or other matters set out in the FOI Act.

    Unless information is personal or commercial and publication would be "unreasonable", anyinformation provided in response to an FOI request will be listed in the Department of Healthand Ageing's FOI disclosure log. It may also be published on a website, or if it not practical to doso, provided on request.

    Documents available outside the FOI Act

    http://www.tga.gov.au/about/ips.htmhttp://www.tga.gov.au/about/foi-documents-released.htmhttp://www.tga.gov.au/about/foi.htm#outsidehttp://www.tga.gov.au/about/foi.htm#outsidehttp://www.tga.gov.au/about/foi-documents-released.htmhttp://www.tga.gov.au/about/ips.htm
  • 8/3/2019 TGA (Autosaved)

    9/34

    How to make a request Fees and charges What you can expect from us If you disagree with our decision Internal review Complaints More information

    Documents available outside the FOI Act

    You should check the information we have published under the Information Publication Schemeand FOI Disclosure Log to see if the information you are seeking is already available.

    How to make a request

    Your request must:

    be in writing state that the request is an application for the purposes of the FOI Act provide sufficient information about the document(s) to allow us to process your request, and provide an address for reply.

    You can send your request:

    By post

    The FOI Coordinator

    Legal Services Branch

    Department of Health and Ageing

    GPO Box 9848

    CANBERRA ACT 2601

    or

    By [email protected]

    If you ask a third party to make an FOI request on your behalf, you need to provide a specific,written authority to send copies of documents to you, care of that person, or to allow that personto inspect copies of documents containing information about you.

    If you require more information, please contact the FOI Contact Officer by [email protected] or calling the Department of Health and Ageing on 1800 020 103 or 02 62891555.

    Fees and charges

    There is no application fee for an FOI request.

    http://www.tga.gov.au/about/foi.htm#howhttp://www.tga.gov.au/about/foi.htm#feeshttp://www.tga.gov.au/about/foi.htm#expecthttp://www.tga.gov.au/about/foi.htm#disagreehttp://www.tga.gov.au/about/foi.htm#internalhttp://www.tga.gov.au/about/foi.htm#complaintshttp://www.tga.gov.au/about/foi.htm#morehttp://www.tga.gov.au/about/ips.htmhttp://www.health.gov.au/internet/main/publishing.nsf/Content/foi-disc-logmailto:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]://www.health.gov.au/internet/main/publishing.nsf/Content/foi-disc-loghttp://www.tga.gov.au/about/ips.htmhttp://www.tga.gov.au/about/foi.htm#morehttp://www.tga.gov.au/about/foi.htm#complaintshttp://www.tga.gov.au/about/foi.htm#internalhttp://www.tga.gov.au/about/foi.htm#disagreehttp://www.tga.gov.au/about/foi.htm#expecthttp://www.tga.gov.au/about/foi.htm#feeshttp://www.tga.gov.au/about/foi.htm#how
  • 8/3/2019 TGA (Autosaved)

    10/34

    There are no processing charges for requests for access to documents containing only personalinformation about you. However, processing charges may apply to other requests. The mostcommon charges are:

    Activity item Charge

    Search and retrieval: time we spend searching for or retrieving a document $15.00 per hour

    Decision making: time we spend in deciding to grant or refuse a request,

    including examining documents, consulting with other parties, and making

    deletions

    First five hours: Nil

    Subsequent hours:$20 per hour

    Transcript: preparing a transcript from a sound recording, shorthand or similar

    medium

    $4.40 per page of

    transcript

    Photocopy $0.10 per page

    Inspection: supervision by an agency officer of your inspection of documents or

    hearing or viewing an audio or visual recording at our premises

    $6.25 per half hour (or

    part thereof)

    Delivery: posting or delivering a copy of a document at your requestCost of postage or

    delivery

    If we decide to impose a charge, we will give you a written estimate and the basis of ourcalculation. Where the estimated charge is between $20 and $100, we may ask you to pay adeposit of $20, or where the estimated charge exceeds $100, we may ask you to pay a 25%

    deposit before we process your request.

    You can ask for the charge to be waived or reduced for any reason, including financial hardshipor on the grounds of public interest. If you do so, you should explain your reasons and you mayneed to provide some evidence.

    What you can expect from us

    We will tell you within 14 days that we have received your request and give you an estimate ofthe charges that apply to your request. We will give you our decision within 30 days unless thattime has been extended. If a document contains information about a third party and we need to

    consult them, the time to give you our decision will be extended by another 30 days. We mayalso seek your agreement to extend the time by up to 30 days if your request is complex.

    Unless the information is personal or is about the commercial, financial or professional affairs ofa person and publication would be "unreasonable", any information provided to you in responseto your request will be listed in the Disclosure Log and published or otherwise made available toanyone who requests access.

  • 8/3/2019 TGA (Autosaved)

    11/34

    If you disagree with our decision

    When we have made a decision about your FOI request, we will send you a letter explaining ourdecision and your review and appeal rights.

    You can ask for the following decisions to be reviewed:

    if we refuse to give you access to all or part of a document or if we defer giving you access if we impose a charge if we refuse to change or annotate information about you that you claim is incomplete, incorrect,

    out of date or misleading.

    A third party who disagrees with our decision to give you documents that contain informationabout them can also ask for our decision about that information to be reviewed.

    Internal review

    You can request in writing that we reconsider our decision through an internal review. Aninternal review will be conducted by another officer in our agency. We will advise you of ournew decision within 30 days of receiving your request.

    Information Commissioner review

    You can ask the Australian Information Commissioner to review our original decision or ourdecision on internal review within 60 days of the date of decision (or 30 days after you arenotified if you are an affected third party). The Information Commissioner can affirm or vary thedecision or substitute a new decision. The Information Commissioner may decide not to conduct

    a review in certain circumstances. More information is available at the Office of the AustralianInformation Commissioner (OAIC) website.

    Complaints

    If you are unhappy with the way we have handled your request, you can complain to theAustralian Information Commissioner who may investigate our actions. More information isavailable on the OAIC's website. The Commonwealth Ombudsman can also investigatecomplaints about our actions. However, the Commonwealth Ombudsman and the InformationCommissioner will consult to avoid the same matter being investigated twice.

    7. TGA business process improvement

    Introduction

    In early 2009, the TGA commenced a significant program of business process reforms (BPRprogram) for the regulation of prescription medicines in Australia. The key elements of the BPRprogram were identified during an industry consultation workshop held on 17 December 2007

    http://www.oaic.gov.au/http://www.oaic.gov.au/http://www.oaic.gov.au/http://www.oaic.gov.au/http://www.oaic.gov.au/http://www.oaic.gov.au/
  • 8/3/2019 TGA (Autosaved)

    12/34

  • 8/3/2019 TGA (Autosaved)

    13/34

    The links below are categorised by topic. This list is also available in an A-Z list.

    Advertising publications Blood, tissues & biologicals publications Complementary medicines publications Import/export publications Labelling & packaging publications Manufacturing publications Medical devices & IVDs publications OTC medicines publications Prescription medicines publications Safety of medicines & medical devices publications Scheduling publications TGA publications

    Advertising publications

    Price information code of practice Schedule 3 advertising guidelines Therapeutic goods advertising code

    Blood, tissues & biologicals publications

    Australian code of GMP for human blood and tissues Australian regulatory guidelines for biologicals (ARGB) Enforcement guidelines Guideline for the preparation of Technical Master Files for blood, blood components and

    haematopoietic progenitor cells TGA biologicals framework newsletter

    Complementary medicines publications

    Analytical procedure validation for complementary medicines Australian regulatory guidelines for complementary medicines (ARGCM) Colourings permitted in medicines for oral use Electronic listing facility (ELF) user guide Enforcement guidelines Guidance on equivalence of herbal extracts in complementary medicines Guidance on product changes in ELF3 Guidance on the use of modified unprocessed herbal materials in complementary medicines Guidelines for levels and kinds of evidence to support indications and claims Identification of herbal materials and extracts Required advisory statements for medicine labels (RASML) Stability testing of Listed complementary medicines Substances that may be used in Listed medicines in Australia TGA approved terminology for medicines

    http://www.tga.gov.au/about/publications-az.htmhttp://www.tga.gov.au/about/publications.htm#advertisinghttp://www.tga.gov.au/about/publications.htm#btbhttp://www.tga.gov.au/about/publications.htm#cmhttp://www.tga.gov.au/about/publications.htm#importhttp://www.tga.gov.au/about/publications.htm#labellinghttp://www.tga.gov.au/about/publications.htm#manufhttp://www.tga.gov.au/about/publications.htm#deviceshttp://www.tga.gov.au/about/publications.htm#otchttp://www.tga.gov.au/about/publications.htm#pmhttp://www.tga.gov.au/about/publications.htm#safetyhttp://www.tga.gov.au/about/publications.htm#schedulinghttp://www.tga.gov.au/about/publications.htm#tgahttp://www.tga.gov.au/industry/advertising-picop.htmhttp://www.tga.gov.au/industry/advertising-schedule3.htmhttp://www.tga.gov.au/industry/legislation-tgac.htmhttp://www.tga.gov.au/industry/manuf-cgmp-human-blood-tissues.htmhttp://www.tga.gov.au/industry/biologicals-argb.htmhttp://www.tga.gov.au/industry/legislation-enforcement-guidelines.htmhttp://www.tga.gov.au/industry/bt-tmf-preparation.htmhttp://www.tga.gov.au/industry/bt-tmf-preparation.htmhttp://www.tga.gov.au/industry/bt-tmf-preparation.htmhttp://www.tga.gov.au/industry/bt-tmf-preparation.htmhttp://www.tga.gov.au/newsroom/biologicals-newsletter.htmhttp://www.tga.gov.au/industry/cm-analytical-procedure.htmhttp://www.tga.gov.au/industry/cm-argcm.htmhttp://www.tga.gov.au/industry/cm-colourings-oral-use.htmhttp://www.tga.gov.au/industry/ebs-elf-userguide.htmhttp://www.tga.gov.au/industry/legislation-enforcement-guidelines.htmhttp://www.tga.gov.au/industry/cm-herbal-extracts-equivalence.htmhttp://www.tga.gov.au/industry/ebs-elf-product-changes.htmhttp://www.tga.gov.au/industry/cm-herbal-modified-unprocessed.htmhttp://www.tga.gov.au/industry/cm-evidence-claims.htmhttp://www.tga.gov.au/industry/cm-identification-herbal-extracts.htmhttp://www.tga.gov.au/industry/labelling-rasml.htmhttp://www.tga.gov.au/industry/cm-stabillity-testing-qa.htmhttp://www.tga.gov.au/industry/cm-listed-substances.htmhttp://www.tga.gov.au/industry/medicines-approved-terminology.htmhttp://www.tga.gov.au/industry/medicines-approved-terminology.htmhttp://www.tga.gov.au/industry/cm-listed-substances.htmhttp://www.tga.gov.au/industry/cm-stabillity-testing-qa.htmhttp://www.tga.gov.au/industry/labelling-rasml.htmhttp://www.tga.gov.au/industry/cm-identification-herbal-extracts.htmhttp://www.tga.gov.au/industry/cm-evidence-claims.htmhttp://www.tga.gov.au/industry/cm-herbal-modified-unprocessed.htmhttp://www.tga.gov.au/industry/ebs-elf-product-changes.htmhttp://www.tga.gov.au/industry/cm-herbal-extracts-equivalence.htmhttp://www.tga.gov.au/industry/legislation-enforcement-guidelines.htmhttp://www.tga.gov.au/industry/ebs-elf-userguide.htmhttp://www.tga.gov.au/industry/cm-colourings-oral-use.htmhttp://www.tga.gov.au/industry/cm-argcm.htmhttp://www.tga.gov.au/industry/cm-analytical-procedure.htmhttp://www.tga.gov.au/newsroom/biologicals-newsletter.htmhttp://www.tga.gov.au/industry/bt-tmf-preparation.htmhttp://www.tga.gov.au/industry/bt-tmf-preparation.htmhttp://www.tga.gov.au/industry/legislation-enforcement-guidelines.htmhttp://www.tga.gov.au/industry/biologicals-argb.htmhttp://www.tga.gov.au/industry/manuf-cgmp-human-blood-tissues.htmhttp://www.tga.gov.au/industry/legislation-tgac.htmhttp://www.tga.gov.au/industry/advertising-schedule3.htmhttp://www.tga.gov.au/industry/advertising-picop.htmhttp://www.tga.gov.au/about/publications.htm#tgahttp://www.tga.gov.au/about/publications.htm#schedulinghttp://www.tga.gov.au/about/publications.htm#safetyhttp://www.tga.gov.au/about/publications.htm#pmhttp://www.tga.gov.au/about/publications.htm#otchttp://www.tga.gov.au/about/publications.htm#deviceshttp://www.tga.gov.au/about/publications.htm#manufhttp://www.tga.gov.au/about/publications.htm#labellinghttp://www.tga.gov.au/about/publications.htm#importhttp://www.tga.gov.au/about/publications.htm#cmhttp://www.tga.gov.au/about/publications.htm#btbhttp://www.tga.gov.au/about/publications.htm#advertisinghttp://www.tga.gov.au/about/publications-az.htm
  • 8/3/2019 TGA (Autosaved)

    14/34

    Import/export publications

    Exporting medicines from Australia - operational guidelines Personal import scheme

    Labelling & packaging publications

    A guide to labelling drugs and poisons Best practice guideline on prescription medicine labelling NDPSC guide to the packaging, labelling and regulation of paints, tinters and related products Required advisory statements for medicine labels (RASML) Tamper-evident packaging code of practice

    Manufacturing publications

    Australian code of GMP for human blood and tissues

    Australian code of good wholesaling practice for medicines in schedules 2, 3, 4 & 8 Australian code of good wholesaling practice for therapeutic goods for human use Enforcement guidelines Guide to interpretation of the Code of GMP for the manufacture of 18-Fludeoxyglucose

    injections Guideline for the preparation of Technical Master Files for blood, blood components and

    haematopoietic progenitor cells Guidelines for sterility testing of therapeutic goods PIC/S explanatory notes for pharmaceutical manufacturers on the preparation of a site master file PIC/S guide for good manufacturing practice for medicinal products

    Medical devices & IVDs publications

    Australian regulatory guidelines for medical devices (ARGMD) Device-medicine boundary products Enforcement guidelines Medical device incident reporting & investigation scheme (IRIS) articles Requirements for the assessment of medical devices containing animal material

    OTC medicines publications

    Australian regulatory guidelines for OTC medicines (ARGOM) Colourings permitted in medicines for oral use

    Enforcement guidelines Guidelines for levels and kinds of evidence to support indications and claims Required advisory statements for medicine labels (RASML) TGA approved terminology for medicines

    Prescription medicines publications

    Australian regulatory guidelines for prescription medicines (ARGPM)

    http://www.tga.gov.au/industry/medicines-approved-terminology.htmhttp://www.tga.gov.au/industry/medicines-approved-terminology.htmhttp://www.tga.gov.au/industry/medicines-approved-terminology.htmhttp://www.tga.gov.au/industry/export-medicines-guidelines.htmhttp://www.tga.gov.au/hp/access-personal-import-scheme.htmhttp://www.tga.gov.au/industry/labelling-drugs-poisons-guide.htmhttp://www.tga.gov.au/industry/labelling-pm-best-practice.htmhttp://www.tga.gov.au/industry/labelling-paints-tinters.htmhttp://www.tga.gov.au/industry/labelling-rasml.htmhttp://www.tga.gov.au/industry/packaging-tamper-evident-cop.htmhttp://www.tga.gov.au/industry/manuf-cgmp-human-blood-tissues.htmhttp://www.tga.gov.au/industry/manuf-medicines-cgwp-schedule2-3-4-8.htmhttp://www.tga.gov.au/industry/manuf-cgwp-tg.htmhttp://www.tga.gov.au/industry/legislation-enforcement-guidelines.htmhttp://www.tga.gov.au/industry/manuf-twg-rsg-18-fludeoxyglucose.htmhttp://www.tga.gov.au/industry/manuf-twg-rsg-18-fludeoxyglucose.htmhttp://www.tga.gov.au/industry/manuf-twg-rsg-18-fludeoxyglucose.htmhttp://www.tga.gov.au/industry/manuf-twg-rsg-18-fludeoxyglucose.htmhttp://www.tga.gov.au/industry/bt-tmf-preparation.htmhttp://www.tga.gov.au/industry/bt-tmf-preparation.htmhttp://www.tga.gov.au/industry/bt-tmf-preparation.htmhttp://www.tga.gov.au/industry/bt-tmf-preparation.htmhttp://www.tga.gov.au/industry/manuf-sterility-testing-guidelines.htmhttp://www.tga.gov.au/industry/manuf-pics-site-master-file.htmhttp://www.tga.gov.au/industry/manuf-pics-gmp-medicines.htmhttp://www.tga.gov.au/industry/devices-argmd.htmhttp://www.tga.gov.au/industry/devices-guidelines-35.htmhttp://www.tga.gov.au/industry/legislation-enforcement-guidelines.htmhttp://www.tga.gov.au/hp/iris-articles.htmhttp://www.tga.gov.au/industry/devices-guidelines-14.htmhttp://www.tga.gov.au/industry/otc-argom.htmhttp://www.tga.gov.au/industry/cm-colourings-oral-use.htmhttp://www.tga.gov.au/industry/legislation-enforcement-guidelines.htmhttp://www.tga.gov.au/industry/cm-evidence-claims.htmhttp://www.tga.gov.au/industry/labelling-rasml.htmhttp://www.tga.gov.au/industry/medicines-approved-terminology.htmhttp://www.tga.gov.au/industry/pm-argpm.htmhttp://www.tga.gov.au/industry/pm-argpm.htmhttp://www.tga.gov.au/industry/medicines-approved-terminology.htmhttp://www.tga.gov.au/industry/labelling-rasml.htmhttp://www.tga.gov.au/industry/cm-evidence-claims.htmhttp://www.tga.gov.au/industry/legislation-enforcement-guidelines.htmhttp://www.tga.gov.au/industry/cm-colourings-oral-use.htmhttp://www.tga.gov.au/industry/otc-argom.htmhttp://www.tga.gov.au/industry/devices-guidelines-14.htmhttp://www.tga.gov.au/hp/iris-articles.htmhttp://www.tga.gov.au/industry/legislation-enforcement-guidelines.htmhttp://www.tga.gov.au/industry/devices-guidelines-35.htmhttp://www.tga.gov.au/industry/devices-argmd.htmhttp://www.tga.gov.au/industry/manuf-pics-gmp-medicines.htmhttp://www.tga.gov.au/industry/manuf-pics-site-master-file.htmhttp://www.tga.gov.au/industry/manuf-sterility-testing-guidelines.htmhttp://www.tga.gov.au/industry/bt-tmf-preparation.htmhttp://www.tga.gov.au/industry/bt-tmf-preparation.htmhttp://www.tga.gov.au/industry/manuf-twg-rsg-18-fludeoxyglucose.htmhttp://www.tga.gov.au/industry/manuf-twg-rsg-18-fludeoxyglucose.htmhttp://www.tga.gov.au/industry/legislation-enforcement-guidelines.htmhttp://www.tga.gov.au/industry/manuf-cgwp-tg.htmhttp://www.tga.gov.au/industry/manuf-medicines-cgwp-schedule2-3-4-8.htmhttp://www.tga.gov.au/industry/manuf-cgmp-human-blood-tissues.htmhttp://www.tga.gov.au/industry/packaging-tamper-evident-cop.htmhttp://www.tga.gov.au/industry/labelling-rasml.htmhttp://www.tga.gov.au/industry/labelling-paints-tinters.htmhttp://www.tga.gov.au/industry/labelling-pm-best-practice.htmhttp://www.tga.gov.au/industry/labelling-drugs-poisons-guide.htmhttp://www.tga.gov.au/hp/access-personal-import-scheme.htmhttp://www.tga.gov.au/industry/export-medicines-guidelines.htm
  • 8/3/2019 TGA (Autosaved)

    15/34

    Best practice guideline on prescription medicine labelling Colourings permitted in medicines for oral use Enforcement guidelines European Union guidelines Guidance for industry on electronic prescription medicine submission dossiers Guideline on prescription medicine discontinuations Literature-based submissions - points to consider Prescription medicine BPR update newsletter Proposal to amend the Required Advisory Statements for Medicine Labels (RASML) Required advisory statements for medicine labels (RASML) TGA approved terminology for medicines

    Safety of medicines & medical devices publications

    Australian Adverse Drug Reactions Bulletin Australian clinical trial handbook Australian pharmacovigilance guideline for sponsors

    Human Research Ethics Committees and the therapeutic goods legislation Joint ADRAC-Medicines Australia guidelines for the design and conduct of company-sponsored

    post-marketing surveillance (PMS) studies Medical device incident reporting & investigation scheme (IRIS) articles Medicines Safety Update Note for guidance on clinical safety data management: definitions and standards for expedited

    reporting Note for guidance on good clinical practice Uniform recall procedure for therapeutic goods (URPTG)

    Scheduling publications

    NCCTG scheduling policy framework The Poisons Standard (the SUSMP)

    TGA publications

    A history of therapeutic goods regulation in Australia TGA advisory committee guidelines TGA News

    9. Regulation basics

    The Australian community expects therapeutic goods in the marketplace to be safe, of highquality and of a standard at least equal to that of comparable countries.

    The TGA is responsible for ensuring that therapeutic goods available for supply in Australia aresafe and fit for their intended purpose. These include goods Australians rely on every day, suchas vitamin pills and bandaids, through to goods used to treat serious conditions, such asprescription medicines, vaccines, blood products and surgical implants.

    http://www.tga.gov.au/industry/pm-argpm.htmhttp://www.tga.gov.au/industry/pm-argpm.htmhttp://www.tga.gov.au/industry/labelling-pm-best-practice.htmhttp://www.tga.gov.au/industry/cm-colourings-oral-use.htmhttp://www.tga.gov.au/industry/legislation-enforcement-guidelines.htmhttp://www.tga.gov.au/industry/pm-euguidelines.htmhttp://www.tga.gov.au/industry/pm-electronic-submission-dossiers.htmhttp://www.tga.gov.au/industry/pm-product-discontinuation.htmhttp://www.tga.gov.au/industry/pm-literature-based-submissions.htmhttp://www.tga.gov.au/newsroom/pm-bpr-newsletter.htmhttp://www.tga.gov.au/industry/labelling-forms-rasml-amend.htmhttp://www.tga.gov.au/industry/labelling-rasml.htmhttp://www.tga.gov.au/industry/medicines-approved-terminology.htmhttp://www.tga.gov.au/hp/aadrb.htmhttp://www.tga.gov.au/industry/clinical-trials-handbook.htmhttp://www.tga.gov.au/safety/australian-pharmacovigilance-guideline.htmhttp://www.tga.gov.au/hp/access-hrec.htmhttp://www.tga.gov.au/safety/adrac-ma-pms-guidelines.htmhttp://www.tga.gov.au/safety/adrac-ma-pms-guidelines.htmhttp://www.tga.gov.au/safety/adrac-ma-pms-guidelines.htmhttp://www.tga.gov.au/safety/adrac-ma-pms-guidelines.htmhttp://www.tga.gov.au/hp/iris-articles.htmhttp://www.tga.gov.au/hp/msu.htmhttp://www.tga.gov.au/industry/clinical-trials-note-ich37795.htmhttp://www.tga.gov.au/industry/clinical-trials-note-ich37795.htmhttp://www.tga.gov.au/industry/clinical-trials-note-ich37795.htmhttp://www.tga.gov.au/industry/clinical-trials-note-ich37795.htmhttp://www.tga.gov.au/industry/clinical-trials-note-ich13595.htmhttp://www.tga.gov.au/industry/recalls-urptg.htmhttp://www.tga.gov.au/industry/scheduling-spf.htmhttp://www.tga.gov.au/industry/scheduling-poisons-standard.htmhttp://www.tga.gov.au/about/history-tg-regulation.htmhttp://www.tga.gov.au/about/committees-expert-guidelines.htmhttp://www.tga.gov.au/newsroom/tga-news.htmhttp://www.tga.gov.au/newsroom/tga-news.htmhttp://www.tga.gov.au/about/committees-expert-guidelines.htmhttp://www.tga.gov.au/about/history-tg-regulation.htmhttp://www.tga.gov.au/industry/scheduling-poisons-standard.htmhttp://www.tga.gov.au/industry/scheduling-spf.htmhttp://www.tga.gov.au/industry/recalls-urptg.htmhttp://www.tga.gov.au/industry/clinical-trials-note-ich13595.htmhttp://www.tga.gov.au/industry/clinical-trials-note-ich37795.htmhttp://www.tga.gov.au/industry/clinical-trials-note-ich37795.htmhttp://www.tga.gov.au/hp/msu.htmhttp://www.tga.gov.au/hp/iris-articles.htmhttp://www.tga.gov.au/safety/adrac-ma-pms-guidelines.htmhttp://www.tga.gov.au/safety/adrac-ma-pms-guidelines.htmhttp://www.tga.gov.au/hp/access-hrec.htmhttp://www.tga.gov.au/safety/australian-pharmacovigilance-guideline.htmhttp://www.tga.gov.au/industry/clinical-trials-handbook.htmhttp://www.tga.gov.au/hp/aadrb.htmhttp://www.tga.gov.au/industry/medicines-approved-terminology.htmhttp://www.tga.gov.au/industry/labelling-rasml.htmhttp://www.tga.gov.au/industry/labelling-forms-rasml-amend.htmhttp://www.tga.gov.au/newsroom/pm-bpr-newsletter.htmhttp://www.tga.gov.au/industry/pm-literature-based-submissions.htmhttp://www.tga.gov.au/industry/pm-product-discontinuation.htmhttp://www.tga.gov.au/industry/pm-electronic-submission-dossiers.htmhttp://www.tga.gov.au/industry/pm-euguidelines.htmhttp://www.tga.gov.au/industry/legislation-enforcement-guidelines.htmhttp://www.tga.gov.au/industry/cm-colourings-oral-use.htmhttp://www.tga.gov.au/industry/labelling-pm-best-practice.htm
  • 8/3/2019 TGA (Autosaved)

    16/34

    A. How therapeutic goods are regulated in

    AustraliaThis topic explains in general terms how therapeutic goods are regulated in Australia. More

    detailed information is available under each of the product areas (see the left navigation).

    a. Medicines and TGA classifications

    28 April 2011

    Within the regulatory framework, medicines are classified into several categories:

    Registered medicineso Prescription (high risk) registeredo Non-prescription (low risk) registered

    Listed medicineso Most over the counter medicines

    Complementary medicinesAssistance in preparing applications

    Professional agents are available to assist in the preparation of applications for listing or

    registering medicines in the Australian Register of Therapeutic Goods. These can be foundthrough ARCS Australia or the relevant industry association. See: Regulatory affairs consultants

    Please note that the TGA makes no representations as to the suitability or performance ofconsultants listed by ARCS or the relevant industry association.

    b. What are 'therapeutic goods'?

    15 August 2011

    Many of us use medicines or medical devices in our daily lives. When we:

    apply a bandage relieve a headache with items from the supermarket take echinacea receive an injection, or undertake a prescribed course of treatment to manage a serious illness.

    http://www.tga.gov.au/industry/regulation-basics-medicines-registered.htmhttp://www.tga.gov.au/industry/regulation-basics-medicines-listed.htmhttp://www.tga.gov.au/industry/cm.htmhttp://www.tga.gov.au/industry/basics-regulatory-affairs-consultants.htmhttp://www.tga.gov.au/industry/basics-regulatory-affairs-consultants.htmhttp://www.tga.gov.au/industry/cm.htmhttp://www.tga.gov.au/industry/regulation-basics-medicines-listed.htmhttp://www.tga.gov.au/industry/regulation-basics-medicines-registered.htm
  • 8/3/2019 TGA (Autosaved)

    17/34

    In relation to the evaluation, assessment and monitoring done by the TGA, therapeutic goods arebroadly defined as products for use in humans in connection with:

    preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury influencing inhibiting or modifying a physiological process testing the susceptibility of persons to a disease or ailment influencing, controlling or preventing conception testing for pregnancy

    This includes things that are:

    used as an ingredient or component in the manufacture of therapeutic goods; or used to replace or modify of parts of the anatomy, or

    Some products, even though they may technically meet the definition of a therapeutic good, aredeclared not to be therapeutic goods under section 7 of the Therapeutic Goods Act 1989.Information on these products is available on this website under the Therapeutic Goods

    (Excluded Goods) Order. Likewise some products that do not meet the definition of a therapeuticgood can be declared to be therapeutic goods in order to allow the TGA to regulate them.

    Is it a medicine or food?

    How a product is presented can help to determine whether it will be treated as a food or amedicine. For example a clove of garlic is a food. However, if it is concentrated and marketed incapsule form with claims that it can be used to relieve cold and 'flu symptoms it will be treated asa medicine.

    A product's principal use is of primary consideration when determining whether it is a food or a

    medicine.

    Sometimes it can be quite difficult to determine if a product is a food or a medicine. In thesecases it is best to contact the experts at the TGA or Food Standards Australia New Zealand.

    Is it a therapeutic good or a cosmetic?

    One of the main factors in determining whether a product is a cosmetic or a medicine (or amedical device) is the claims made about the product. For example, moisturisers which contain asunscreening agent as a secondary component and have a stated therapeutic purpose (e.g. 'helpsprotect skin from the damaging effects of UV radiation') are medicines.

    Even if a product is intended for marketing as a cosmetic, it may be classified as a medicine thisdepends on:

    its ingredients, the route of administration, or if therapeutic claims are made on its label, or in advertising.

    http://www.tga.gov.au/industry/legislation-excluded-goods.htmhttp://www.tga.gov.au/industry/legislation-excluded-goods.htmhttp://www.tga.gov.au/industry/legislation-excluded-goods.htmhttp://www.tga.gov.au/industry/legislation-excluded-goods.htm
  • 8/3/2019 TGA (Autosaved)

    18/34

    Sometimes it can be quite difficult to determine if you product is a therapeutic good or acosmetic. In these cases it is best to contact the experts at the TGA or the National IndustrialChemicals Notification and Assessment Scheme.

    c. How the TGA regulatesOverview

    The Australian community expects therapeutic goods in the marketplace to be safe, of highquality and of a standard at least equal to that of comparable countries.

    The TGA regulates therapeutic goods through:

    pre-market assessment; post-market monitoring and enforcement of standards; and

    licensing of Australian manufacturers and verifying overseas manufacturers' compliance with thesame standards as their Australian counterparts.

    Therapeutic goods are divided broadly into two classes: medicines and medical devices.Medicines must be entered as either 'registered' or 'listed' medicines and medical devices must be'included' on the Australian Register of Therapeutic Goods (ARTG) before they may be suppliedin or exported from Australia, unless exempted.

    If a problem is discovered with a medicine, device or manufacturer, the TGA is able to takeaction. Possible regulatory actions vary from continued monitoring to withdrawing the productfrom the market.

    Risk management

    The TGA approves and regulates products based on an assessment of risks against benefits.

    All therapeutic goods have risks, some of which are insignificant, some serious. The TGAapplies scientific and clinical expertise to its decision-making to ensure that the benefits of aproduct outweigh any risk.

    In assessing the level of risk, factors such as side effects, potential harm through prolonged use,toxicity and the seriousness of the medical condition for which the product is intended to be

    used, are all taken into account. For example, some blood pressure medications may include sideeffects such as a tickle in the throat or persistent cough, but this risk is outweighed by the provenbenefits of reducing the risk of a heart attack or stroke.

    The level of TGA regulatory control increases with the level of risk the medicine or device canpose. Risk information is used by the TGA when deciding how to approve a medication forsupply. For example, a low-risk product may be safely sold through supermarkets, while higher-risk products may only be supplied with a prescription.

    http://www.nicnas.gov.au/http://www.nicnas.gov.au/http://www.nicnas.gov.au/http://www.nicnas.gov.au/
  • 8/3/2019 TGA (Autosaved)

    19/34

    The TGA's approach to risk management involves:

    identifying, assessing and evaluating the risks posed by therapeutic products applying any measures necessary for treating the risks posed; and monitoring and reviewing risks over time.

    The risk-benefit approach assures consumers that the products they take are safe for theirintended use, while still providing access to products that are essential to their health needs.

    d. Role of the sponsor

    Under the Therapeutic Goods Act 1989, a 'Sponsor' is someone who:

    imports therapeutic goods, manufactures therapeutic goods, has therapeutic goods imported or manufactured on their behalf, or exports therapeutic goods from Australia.

    The sponsor of a medicine is the person or company responsible for applying to the TGA to havetheir medicine included in the Australian Register of Therapeutic Goods.

    e. The TGA's risk management approach

    12 September 2011

    The Australian community has an expectation that therapeutic goods are safe and of high quality,to a standard equal to that in comparable countries. The objective of the Therapeutic Goods Act1989 (the TG Act) is to provide a national framework for the regulation of therapeutic goods inAustralia, so as to ensure their quality, safety, efficacy and timely availability.

    The Therapeutic Goods Administration (TGA), as part of the Australian GovernmentDepartment of Health and Ageing, has responsibility for administering the TG Act. Essentially,any product for which therapeutic claims are made must be included in the Australian Register ofTherapeutic Goods (ARTG) before it can be supplied in Australia. The exceptions to thisrequirement are if a product is subject to one of the limited exemptions set out in the legislation.

    The TGA adopts a risk management approach to regulating therapeutic goods.

    In essence, this means that the TGA:

    identifies, assesses and evaluates the risks posed by therapeutic goods; applies any measures necessary for treating the risks posed; and monitors and reviews the risks over time.

    http://www.tga.gov.au/industry/artg.htmhttp://www.tga.gov.au/industry/artg.htm
  • 8/3/2019 TGA (Autosaved)

    20/34

    The purpose of this document is to describe the broad risk management approach adopted by theTGA. It is intended that this document will be updated as the regulatory systems changes throughfuture legislative amendments.

    B. Australian Register of Therapeutic GoodsRelated information

    Searching the ARTGTherapeutic goods must be entered on the Australian Register of Therapeutic Goods (ARTG)before they can be lawfully supplied in Australia.

    Information held in the ARTG

    Information held in the ARTG includes:

    product name and formulation details sponsor (company) and manufacturer details

    View public, sponsor or manufacturer information on the ARTG

    There were approximately 62,600 products on the Australian Register of Therapeutic Goods as atJanuary 2011.

    Current medicines Current medical devices

    Access to therapeutic goods not on the ARTG

    As with many aspects of the regulatory framework, there are situations where special policieshave been developed in response to the needs of particular people or circumstances. Informationon these policies and the relevant procedures can be found at:

    Special access scheme Authorised prescribers Personal import scheme Clinical trials exemption scheme

    These schemes cannot be used to facilitate the commercial supply of therapeutic goods.

    C. advertising therapeutic goods

    Advertisements for therapeutic goods can be presented in several forms, including:

    http://www.tga.gov.au/industry/artg-searching.htmhttps://www.ebs.tga.gov.au/ebs/ANZTPAR/PublicWeb.nsf/cuMedicines?OpenViewhttps://www.ebs.tga.gov.au/ebs/ANZTPAR/PublicWeb.nsf/cuDevices?OpenViewhttps://www.ebs.tga.gov.au/ebs/ANZTPAR/PublicWeb.nsf/cuDevices?OpenViewhttps://www.ebs.tga.gov.au/ebs/ANZTPAR/PublicWeb.nsf/cuMedicines?OpenViewhttp://www.tga.gov.au/industry/artg-searching.htm
  • 8/3/2019 TGA (Autosaved)

    21/34

    magazines newspapers television radio Internet

    Posters Billboards medical journals

    Certain advertisements directed at consumers require approval prior to broadcast or publication.

    Advertising to consumers is permitted for the majority of medicines available for over thecounter sale, while advertising prescription-only and certain pharmacist-only medicines to thegeneral public is prohibited. (However, government-controlled public health campaigns that havebeen approved by Health Ministers are exempt from this prohibition).

    The advertising of therapeutic goods to consumers and health practitioners is controlled by acombination of statutory measures administered by the TGA and self-regulation through Codesof Practice administered by the relevant therapeutic goods industry associations.

    Advertisements for therapeutic goods in Australia are subject to the requirements ofthe Therapeutic Goods Act 1989 and Regulations, the Competition and Consumer Act 2010 andother relevant laws. Advertisements for therapeutic goods directed to consumers must alsocomply with the Therapeutic Goods Advertising Code.

    The purpose of these requirements is to protect public health by promoting the safe use oftherapeutic goods, ensuring that they are honestly promoted as to their benefits, uses and effects.

    Further information, on Australia's co-regulatory system of advertising for therapeutic goods,including details of the Therapeutic Goods Advertising Code Council (TGACC), the ComplaintsResolution Panel and the Complaints Register, may be obtained from the TGACC Internet site.

    D. Labelling & packaging

    a. Labelling and packaging review

    9 August 2011

    The TGA is initiating a review of the labelling and packaging regulatory framework forprescription medicines, over the counter medicines and complementary medicines.

    The report Review to improve the transparency of the Therapeutic Goods Administration (TGATransparency Review Report), contains recommendations relating to the labelling of medicines.The Gillard Government has yet to accept the recommendations. As part of the labelling and

    http://www.tga.gov.au/industry/legislation-tgac.htmhttp://www.tgacc.com.au/http://www.tga.gov.au/newsroom/review-tga-transparency-1101.htmhttp://www.tga.gov.au/newsroom/review-tga-transparency-1101.htmhttp://www.tgacc.com.au/http://www.tga.gov.au/industry/legislation-tgac.htm
  • 8/3/2019 TGA (Autosaved)

    22/34

    packaging review, the TGA will be considering the submissions to the review and the relevantsections of the report.

    Subject to the outcomes of the government's consideration of the TGA Transparency ReviewReport, it is anticipated that the labelling and packaging review consultation paper will be

    released in October 2011.

    b. A guide to labelling drugs and poisons

    26 October 2007

    The Standard for the Uniform Scheduling of Drugs and Poisons (SUSDP) contains certain legalrequirements for the labelling of poisons and drugs that are for sale to the public. The labellingsystem it contains was initially designed to harmonise the requirements of Australia and NewZealand and was phased in over a five year period which commenced on 1 July 1995 and ended

    on 30 June 2000. In July 2004 the Required Advisory Statements for Medicine Labels (RASML)document was established by the Therapeutic Goods Administration to enable the transfer of allmandatory label advisory statements from the SUSDP and the Therapeutic Goods Regulations toa new document, separate from but linked to TGO 69 - General requirements for labels formedicines (the Labelling Order). The Labelling Order makes it mandatory for medicine labels toinclude any label advisory statements specified in Required Advisory Statements for MedicineLabels. The RASML provided a one-year transition period for existing products and took fulleffect on 1 July 2005. As a consequence the majority of SUSDP medicines advisory labellingrequirements were replaced with references to the RASML, effective May 2006.

    This Guide has been prepared to assist manufacturers and packers of poisons to draft labels

    which comply with the SUSDP requirements as they exist on 1 January 2007. The information itcontains is not complete nor is it intended to be the sole source of reference. It is essential forusers of this Guide to also refer to the SUSDP and Commonwealth, State or Territory legislationwhich relate to the packaging and labelling of drugs, poisons, therapeutic goods, agriculturalchemicals and veterinary chemicals. To assist the reader to refer back to the SUSDP, referencesto relevant paragraphs and sub-paragraphs have been included in this Guide.

    c. Best Practice Guideline on Prescription Medicine Labelling

    1. Space for the Pharmacist's Label

    There should be a clear space for the pharmacist's dispensing label measuring a minimum of 80 x40 mm. This is the size of the most commonly used computer-printed dispensing label. Thismeans that after the pharmacist has labelled the package the following essential information willstill be visible and that it should remain visible after the pharmacist has attached the dispensinglabel:

    Batch number Expiry date Storage instructions

    http://www.tga.gov.au/industry/scheduling-poisons-standard.htmhttp://www.comlaw.gov.au/Details/F2009C00264http://www.comlaw.gov.au/Details/F2009C00264http://www.comlaw.gov.au/Details/F2009C00264http://www.comlaw.gov.au/Details/F2009C00264http://www.tga.gov.au/industry/scheduling-poisons-standard.htm
  • 8/3/2019 TGA (Autosaved)

    23/34

    Product name Strength Name of the active ingredient(s) Dose form Barcode (EAN barcode) Signal headings Warning statements AUSTR number

    If the product is packaged in a small container, such as eye drops, consideration should be givento use of a cardboard backboard that would allow space for a pharmacist's label. This should beon the primary container.

    Words to the effect 'Place label here' should be placed in the designated Pharmacy Label space.Ideally, if there are mandatory warning labels required, space should be provided.

    2. Batch Number and Expiry Date

    The batch number and expiry date should be positioned together and situated preferably on theend or side panel of the package.

    The batch number and expiry date should be easily legible; for example ink is preferred overembossing. For eye preparations and other topicals, the words "after opening use within [xx]days" should be on the label. See TGO for mandatory requirements.

    Top of page

    3. Storage Conditions

    Ideally, the storage conditions should be located close to the batch number and expiry date, andpreferably on the front or side panels as end panels are already filled with product / activeingredient names and / or batch expiry information.

    4. Barcode

    An EAN barcode can be used to facilitate electronic aids in dispensing and as a means of double-checking that this is the correct product to be dispensed. To be effective, it must be located sothat it will not be covered by the pharmacist's dispensing label and can still be scanned after thepharmacist has affixed the dispensing label.

    5. Product Name and Strength

    Both the product name and the active ingredient names and strength should be prominently andequally displayed on the packet on at least three sides, including the two end panels. Strength andquantity should also be displayed. To assist in easy storage and reference both product and activeingredient names and strength / quantity should be displayed on end panels, with the first namealternating between the two end panels. To distinguish between the product name and the active

    http://www.tga.gov.au/industry/labelling-pm-best-practice.htm#topofpagehttp://www.tga.gov.au/industry/labelling-pm-best-practice.htm#topofpage
  • 8/3/2019 TGA (Autosaved)

    24/34

    ingredient name, the first letter of the product name should be in upper case and of the activeingredient name in lower case with a different colour for each. Fonts may be used todifferentiate, but all fonts should be clearly legible.

    There should be consistency in terminology to describe strength. All products in one product line

    should follow the same convention.

    The use of 5mg/5mL and 10mg/mL for two products in a product line is strongly discouraged.Expressions of strength should be consistent throughout all labelling, including ProductInformation (PI) and Consumer Medicine Information (CMI). See TGO for mandatoryrequirements.

    6. Dose Form

    Terminology concerning the long-acting dose forms should be accurate, relate to the product andbe clearly specified on the label. For example, extended release, sustained release, controlled

    release or modified release are sometimes used.

    7. Packaging Colour and Design

    The use of colour and design should not unnecessarily clutter or obscure the message of thelabels but make them clear and distinguishable.

    Pictures or graphics should be meaningful, appropriate, and represent the use of a medicine, andnot suggest an unapproved use. Consideration should be given to including a graphicalrepresentation of the tablet on the outer packet.

    If using "corporate livery" companies should consider using other design elements (colour bands,positioning of text, boxes around text, reversed out printing) to assist distinguishing betweenproducts within their total product range and between different strengths and presentations.

    Use of different colours or colour bars to distinguish between different strengths or presentationsof the product is encouraged. A visual signal may be given if stronger colours are used for higherstrength products and light shades for lower strength products.

    If undertaking extensive changes to presentation, relevant user testing tailored to the needs of theparticular user group is recommended.

    Top of page

    8. Tamper-evident Packaging

    The tamper-evident packaging should not interfere with the ability of the pharmacist to place thedispensing label.

    http://www.tga.gov.au/industry/labelling-pm-best-practice.htm#topofpagehttp://www.tga.gov.au/industry/labelling-pm-best-practice.htm#topofpage
  • 8/3/2019 TGA (Autosaved)

    25/34

    9. Specific Australian Issues

    Compliance with the following best practice recommendations will be taken by the TGA asacceptable:

    Potassium labelling: It is imperative that all concentrated potassium products for injection orinfusion should be packaged in a manner that uniquely identifies them.

    The ampoules and vials should be clearly labelled as Potassium Chloride or the relevant salt; theend of the ampoules should contain "KCl", or equivalent, in large lettering. The strength is to beprominently displayed as both millimoles and total content and strength in millimoles/litre; theinstruction, "dilute before use" should be included; there should be a black block of colour on the"twist off" tab at the top of the ampoule. In relation to the vial, there should be a black "twist off"seal on the cap of the vial.

    The premixed bags should only use red lettering for labelling. 'Potassium' should be in letters

    written vertically on the left hand side of the panel as well as horizontally, both in the largest fontused on the label; concentration and content in millimoles should be displayed prominently anddisplayed next to the letters "Potassium". The words "Potassium chloride" (or equivalent) shouldalso be displayed in large letters in the label. There should be a clear space at least equivalent tothe maximum font size around main description and key information (such as diluent andvolume).

    Vinca alkaloids: All products should be prominently labelled firstly with, "To be givenintravenously only" followed by, "Fatal if given by any other routes".

    Methotrexate: Confusion has arisen because this product can be prescribed once weekly or

    sometimes at more frequent intervals in either the community or hospital setting.

    There should be clear instructions, "Check dose and frequency - methotrexate is usually takenonce a week". Sponsors are encouraged to consider packaging methotrexate in indication-specific weekly or daily packs to assist in reducing errors.

    10. General issues

    Consideration should be given to including a diagram or other visual depiction of the product,such as individual tablets/capsules etc, with identification codes, and/or a description on theouter pack.

    Avoid labels that easily detach from the container. See also TGO for mandatory requirements.

    To avoid ambiguity of the message, only positive statements should appear on medicine labels.For example, "For intravenous use only" is preferred to a negative statement such as "not forintravenous use".

  • 8/3/2019 TGA (Autosaved)

    26/34

    Distinctive tablet markings may assist in identification of products and should be considered inproduct development.

    To distinguish between the product name and the active ingredient, the first letter of the productname should be in upper case and the first letter of the active ingredient should be in lower case.

    Consideration should be given to ensuring packaging is designed to meet the needs of intendedrecipients in terms of access.

    11. Blister packaging

    Ideally for blister packaging, each blister cover should include both the active and the productnames, and the strength, batch number and expiry date of the medicine. However, this is notalways possible. In cases where blisters are small, repetitive diagonal use of product names overthe blister covers with expiry date and batch number on the side can assist with identification ofpartly used packs.

    High-risk dependency products, eg opioids & benzodiazepines, should be packed in blister packswhere possible to facilitate accountability and reduce impulse ingestion. The use of gel capsshould be avoided. Consideration should be given to packaging parenteral high risk dependencyproducts in glass or otherwise take steps to reduce the risk of tampering.

    12. Choice of product names

    Product names for prescription medicines should clearly identify the product. They should beunique, but neither promotional nor offensive in relation to general community standards.Umbrella branding is strongly discouraged in prescription medicine labelling. The product namecould be based on the active ingredient name with the company identified.

    Product names can be confused with other product names if care is not taken in their selection. Inchoosing a product name there should be comparative testing to existing product names, for bothprescription and non-prescription medicines. This should involve a review using the lettersforming the name, the sound of the name and analysis of recognition by electronic databases, aswell as handwriting. Ideally, consumer and/or health professionals will be used in focus usertesting and results provided to the TGA.

    13. Combination products

    For combination products, the names of all active ingredients should be used in equal

    prominence to the product name for the product itself. The product name of the product must beclearly differentiated from the product names for any of the ingredients. The quantities of theactive ingredients should be clearly visible and may be incorporated in the product name. Forproduct ranges, the quantities of the actives should be incorporated into the product namewherever possible, for example "XYZ 20/10". Alternatively, or in addition, the words"combination therapy" should be added under the product name.

  • 8/3/2019 TGA (Autosaved)

    27/34

    14. New Line Products

    If introducing new products to an existing range, consideration must be given to the potential forconfusion with existing medicines. This may mean that not only will the new product havedistinctive labelling, but revision of the existing product labelling may also be required.

    15. Use of product names in other documents

    Consumer Medicine Information

    The CMI should contain both active and product names at the beginning of the document. Use ofproduct name is only encouraged where information relates to that product of the medicine. Useof active ingredient name for negative information only is not acceptable.

    Product Information

    The product name should not be used only to present positive information in the productlabelling, nor the generic name used to present only negative information associated with theproduct. The product name should only be used where the information only applies to thecharacteristics of the branded product, for example, the description, form of presentation,strength, method of use and dosage.

    E. Import & export

    Importing therapeutic goods

    Most products for which therapeutic claims are made must be listed or registered in the Australian

    Register of Therapeutic Goods (ARTG) before they can be supplied in Australia.

    Exporting therapeutic goods

    Safety and quality in medicines are not just a local matter. The increasing globalisation of trademeans that our responsibilities continue beyond the limit of our territorial waters.

    The Therapeutic Goods Act 1989 applies to both the supply of therapeutic goods in Australia andthe export of therapeutic goods from Australia.

    A key requirement of the legislation is that all therapeutic goods must be included in the

    Australian Register of Therapeutic Goods (ARTG), including those that are exported.

    There are processes and controls that you need to be aware of when applying to exporttherapeutic goods.

    F. Cosmetics

  • 8/3/2019 TGA (Autosaved)

    28/34

    The TGA only assesses cosmetic products that make therapeutic claims.

    Many ingredients in cosmetic products are classed as industrial chemicals and the NationalIndustrial Chemicals Notification Assessment Scheme (NICNAS) must be notified of allcosmetics that contain industrial chemicals new to Australia.

    In September 2007, a new framework for the regulation of cosmetic products was implementedfollowing amendments to the Industrial Chemicals (Notification and Assessment) Act 1989. ThisAct is administered by the National Industrial Chemicals Notification and Assessment Scheme(NICNAS). The Act legally underpins the Cosmetics Standard 2007 and this Standard issupported by the NICNAS Cosmetic Guidelines 2007. Both documents are available from theNICNAS website.

    To assist with facilitating this new regulatory framework, on 11 June 2008 the TGA adopted anew Therapeutic Goods (Excluded Goods) Order No. 1 of 2008. On 31 May 2011 TherapeuticGoods (Excluded Goods) Order No. 1 of 2008 was revoked by Therapeutic Goods (Excluded

    Goods) Order No. 1 of 2011.

    Enquiries about the regulation of cosmetic products should be directed to NICNAS in the firstinstance.

    10. Committees

    A. Statutory expert committees

    The TGA has six statutory expert committees it may call upon to obtain independent advice onscientific and technical matters.

    Committee members are appointed by the Minister and must have expertise in relevant clinicalor scientific fields or appropriate consumer issues.

    1. Advisory Committee on Complementary

    Medicines (ACCM)

    Role of ACCM

    The Advisory Committee on Complementary Medicines (ACCM) was formed in January 2010to advise and make recommendations to the Therapeutic Goods Administration (TGA) on theinclusion, variation or retention of a complementary medicine in the Australian Register ofTherapeutic Goods.

    http://www.nicnas.gov.au/Current_Issues/Cosmetics.asphttp://www.tga.gov.au/industry/legislation-excluded-goods-order-1101.htmhttp://www.tga.gov.au/industry/legislation-excluded-goods-order-1101.htmhttp://www.nicnas.gov.au/http://www.nicnas.gov.au/http://www.tga.gov.au/industry/legislation-excluded-goods-order-1101.htmhttp://www.tga.gov.au/industry/legislation-excluded-goods-order-1101.htmhttp://www.nicnas.gov.au/Current_Issues/Cosmetics.asp
  • 8/3/2019 TGA (Autosaved)

    29/34

    ACCM may also provide advice to the TGA on any other matters concerning complementarymedicines, and any other matters referred to it by the TGA (whether or not related to acomplementary medicine).

    ACCM supersedes the Complementary Medicines Evaluation Committee (CMEC) and has an

    increased focus on the advisory role within the regulatory framework of complementarymedicines.

    A major role for ACCM is to provide scientific and policy advice relating to controls on thesupply and use of complementary medicines in Australia. The ACCM provides this advice withparticular reference to the safety and quality of products and, where appropriate, efficacy relatingto the claims made for products.

    2. Advisory Committee on Medical Devices

    (ACMD)Role of ACMD

    The Advisory Committee on Medical Devices (ACMD) provides independent medical andscientific advice to the Minister and the Therapeutic Goods Administration (TGA) on safety,quality and performance of medical devices supplied in Australia including issues relating topremarket conformity assessment and post market monitoring.

    The Committee is established under Regulation 38 of the Therapeutic Goods Regulations 1990and the members are appointed by the Minister for Health and Ageing.

    On 1 January 2010 changes were made to the Therapeutic Goods Regulations 1990, whichestablished the ACMD in place of the previous Committee, the Medical Devices EvaluationCommittee.

    3. Advisory Committee on Non-prescription

    Medicines (ACNM)

    Role of ACNM

    The Advisory Committee on Non-prescription Medicines (ACNM) was formed in January 2010.The ACNM advise and make recommendations to the TGA regarding the entry of non-prescription medicines on the Australian Register of Therapeutic Goods (the Register). Thisincludes:

    inclusion of a non-prescription medicine on the Register changes to an entry of a non-prescription medicine on the Register

    http://www.tga.gov.au/archive/committees-cmec.htmhttp://www.tga.gov.au/archive/committees-mdec.htmhttp://www.tga.gov.au/archive/committees-mdec.htmhttp://www.tga.gov.au/archive/committees-mdec.htmhttp://www.tga.gov.au/archive/committees-mdec.htmhttp://www.tga.gov.au/archive/committees-cmec.htm
  • 8/3/2019 TGA (Autosaved)

    30/34

    removal or retention of a non-prescription medicine on the Register.ACNM may also provide advice to the TGA on other matters concerning a non-prescriptionmedicine, and any other matters referred to it by the TGA.

    The ACNM supersedes the Medicines Evaluation Committee (MEC).

    4. Advisory Committee on Prescription

    Medicines (ACPM)

    Role of ACPM

    The Advisory Committee on Prescription Medicines (ACPM) was formed in January 2010. TheACPM advises and makes recommendations to the TGA on prescription medicines. This

    includes:

    inclusion of a prescription medicine on the Australian Register of Therapeutic Goods (theRegister)

    changes to an entry of a prescription medicine on the Register removal or retention of a prescription medicine on the Register.

    ACPM may also provide advice to the Minister or the Secretary, through the TGA on othermatters concerning a prescription medicine, and any other matters referred to it by the Ministeror the Secretary.

    The ACPM is the successor of the Australian Drug Evaluation Committee (ADEC), which wasformed in 1963.

    5. Advisory Committee on the Safety of

    Medicines (ACSOM)

    Role of ACSOM

    The Advisory Committee on the Safety of Medicines (ACSOM) was formed in January 2010 to

    advise and make recommendations to the TGA on the:

    safety of medicines risk assessment and risk management of medicines

    ACSOM may also provide advice to the TGA on other matters related to the detection,assessment, understanding and prevention of adverse effects, known as pharmacovigilance, andany other matters referred to it by the TGA.

    http://www.tga.gov.au/archive/committees-mec.htmhttp://www.tga.gov.au/archive/committees-adec.htmhttp://www.tga.gov.au/archive/committees-adec.htmhttp://www.tga.gov.au/archive/committees-mec.htm
  • 8/3/2019 TGA (Autosaved)

    31/34

    ACSOM supersedes and expands upon the role of the Adverse Drug Reactions AdvisoryCommittee (ADRAC) with an increased focus on the safety aspects of medicine regulation andthe detection, assessment, understanding and prevention of adverse effects.

    A major role for ACSOM is to provide advice on the quality and appropriateness of risk

    management plans which are designed to define and pro-actively manage risks relating to amedicine over its entire life cycle.

    6. Therapeutic Goods Committee (TGC)

    Role of the TGC

    The Therapeutic Goods Committee (TGC) is established under regulation 34 of the TherapeuticGoods Regulations 1990 (the regulations) to advise and make recommendations to the Ministerfor Health and Ageing on the adoption of standards for therapeutic goods, matters relating to

    standards for therapeutic goods, including requirements for labelling and packaging andstandards for manufacture of therapeutic goods, and matters relating to medical device standardsand conformity assessment standards.

    For further details on the role and operation of the TGC, refer to the Therapeutic GoodsRegulations 1990.

    B. Other committees

    1. Advisory committees on medicines &chemicals scheduling (ACMS & ACCS)

    Role of the ACMS and the ACCS

    Scheduling is a classification system that controls how medicines and chemicals are accessible toconsumers. Medicines and chemicals are grouped into Schedules according to the appropriatelevel of regulatory control over their availability (e.g. Schedule 4 - medicines available only byprescription; Schedule 2 - medicines available over the counter in pharmacies).

    Under revised scheduling arrangements, which took effect on 1 July 2010, the Secretary to theDepartment of Health and Ageing (DoHA) (or the Secretary's delegate) superseded the NationalDrugs and Poisons Schedule Committee (NDPSC) as the decision maker for the scheduling ofmedicines and chemicals. The revised arrangements also established two expert advisorycommittees, the Advisory Committee on Medicines Scheduling (ACMS) and the AdvisoryCommittee on Chemicals Scheduling (ACCS), as statutory committees under the TherapeuticGoods Act 1989 (the Act) to advise and make recommendations to the Secretary of the DoHA(or delegate) on the level of access required for medicines and chemicals.

    http://www.tga.gov.au/archive/committees-adrac.htmhttp://www.tga.gov.au/archive/committees-adrac.htmhttp://www.tga.gov.au/industry/legislation.htmhttp://www.tga.gov.au/industry/legislation.htmhttp://www.tga.gov.au/industry/scheduling-background-2010.htmhttp://www.tga.gov.au/archive/committees-ndpsc.htmhttp://www.tga.gov.au/archive/committees-ndpsc.htmhttp://www.tga.gov.au/archive/committees-ndpsc.htmhttp://www.tga.gov.au/archive/committees-ndpsc.htmhttp://www.tga.gov.au/industry/scheduling-background-2010.htmhttp://www.tga.gov.au/industry/legislation.htmhttp://www.tga.gov.au/industry/legislation.htmhttp://www.tga.gov.au/archive/committees-adrac.htmhttp://www.tga.gov.au/archive/committees-adrac.htm
  • 8/3/2019 TGA (Autosaved)

    32/34

    2. Australian Influenza Vaccine Committee

    (AIVC)

    3. National Coordinating Committee onTherapeutic Goods (NCCTG)

    4. Regulatory and Technical Consultative

    Forum for medical devices (RegTech Forum)

    11. TGA eBusiness services

    TGA eBusiness Services (eBS) is an online portal that provides separate functions for consumers, health

    professionals and industry.

    A. For Consumers and Health Professionals

    eBS hosts the Australian Register of Therapeutic Goods (ARTG), and provides publicallyavailable information about current medicines and medical devices.

    How to search the ARTG Current medicines Current medical devices

    eBS offers an online reporting system for consumers and health professionals to report anadverse reaction to a medicine or medical device, and for industry to lodge a recall request for adeficient or defective medicine.

    Report adverse drug reactions

    eBS lists Consumer Medicines Information (CMI) and Product Information (PI) for public accessand download.

    A CMI is a leaflet that contains consumer information on the safe and effective use of amedicine.

    A PI provides health professionals with a summary of the essential scientific information toallow the safe and effective use of a medicine under nearly all circumstances.

    http://www.tga.gov.au/industry/artg-searching.htmhttp://www.tga.gov.au/industry/artg-searching.htmhttps://www.ebs.tga.gov.au/ebs/ANZTPAR/PublicWeb.nsf/cuMedicines?OpenViewhttps://www.ebs.tga.gov.au/ebs/ANZTPAR/PublicWeb.nsf/cuMedicines?OpenViewhttps://www.ebs.tga.gov.au/ebs/ANZTPAR/PublicWeb.nsf/cuDevices?OpenViewhttps://www.ebs.tga.gov.au/ebs/ANZTPAR/PublicWeb.nsf/cuDevices?OpenViewhttps://www.ebs.tga.gov.au/ebs/ADRS/ADRSRepo.nsf?OpenDatabasehttps://www.ebs.tga.gov.au/ebs/ADRS/ADRSRepo.nsf?OpenDatabasehttps://www.ebs.tga.gov.au/ebs/ADRS/ADRSRepo.nsf?OpenDatabasehttps://www.ebs.tga.gov.au/ebs/ANZTPAR/PublicWeb.nsf/cuDevices?OpenViewhttps://www.ebs.tga.gov.au/ebs/ANZTPAR/PublicWeb.nsf/cuMedicines?OpenViewhttp://www.tga.gov.au/industry/artg-searching.htm
  • 8/3/2019 TGA (Autosaved)

    33/34

    B. For Industry

    eBS allows industry to manage some therapeutic good registration applications, and view andcancel their current entries on the ARTG. Sponsors are able to view, download and print ARTGRegister entries for their products and generate certificates online.

    Users are able to keep up to date with the latest TGA-wide and Industry specific newsdirectlyfrom the portal.

    eBS provides information on TGA approved Australian manufacturers and TGA approvedingredient names and terminology that can be used in online applications for therapeutic productentry onto the ARTG.

    View approved terminology/code tables Australian manufacturers licensed to manufacture therapeutic goods

    To apply for access to TGA eBusiness Services please see theeBS access forms, please note thisaccess is only available to Industry, that is sponsors, agents or manufacturers.

    https://www.ebs.tga.gov.au/https://www.ebs.tga.gov.au/https://www.ebs.tga.gov.au/https://www.ebs.tga.gov.au/
  • 8/3/2019 TGA (Autosaved)

    34/34